论文部分内容阅读
目的:探讨舟山海岛地区非小细胞肺癌患者表皮生长因子受体(EGFR)19、21外显子的基因突变发生率及其与临床病理特征的相关性。方法:应用PCR扩增产物直接测序法检测129例非小细胞肺癌患者肿瘤组织EGFR基因19、21外显子突变,并分析其与临床病理资料的相关性。结果:129例肺癌患者中,共有35例发生EGFR基因突变(27.1%)。女性、非吸烟、腺癌及中高分化NSCLC患者EGFR基因突变率较高,是引起EGFR基因突变的危险因素(P<0.05)。Kaplan-Meier生存分析显示,NSCLC患者EGFR基因野生型及突变型生存率比较差异无统计学意义(P>0.05)。结论:舟山海岛地区肺癌患者EGFR突变发生率为27.1%,在女性、非吸烟、中高分化及肺腺癌患者中多见,但与总生存时间无明显相关。
Objective: To investigate the incidence of gene mutations in exon 19 and 21 of epidermal growth factor receptor (EGFR) in patients with non-small cell lung cancer in Zhoushan island and its correlation with clinicopathological features. Methods: The exon 19 and 21 of EGFR gene in 129 cases of non-small cell lung cancer were detected by direct sequencing of PCR amplification products and their correlation with clinicopathological data was analyzed. Results: Of the 129 patients with lung cancer, a total of 35 patients had EGFR gene mutation (27.1%). The mutation rate of EGFR gene is higher in female, non-smoking, adenocarcinoma and moderately-differentiated NSCLC patients, which is the risk factor of EGFR gene mutation (P <0.05). Kaplan-Meier survival analysis showed that there was no significant difference in EGFR gene wild type and mutation survival rate between NSCLC patients (P> 0.05). Conclusion: The incidence of EGFR mutation in lung cancer patients in Zhoushan island area was 27.1%, which was more common in female, non-smoking, moderately-differentiated and lung adenocarcinoma patients, but not with the overall survival time.